Identification and functional analyses of molecular haplotypes of the human osteoprotegerin gene promoter

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 10, 2009, Pages 1638-1643

  Hagedorn, Claudia ^a   Telgmann, Ralph ^a   Dördelmann, Corinna ^a   Schmitz, Boris ^a   Hasenkamp, Sandra ^b   Cambien, François ^c   Paul, Martin ^d   Brand, Eva ^b   Brand Herrmann, Stefan Martin ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c INSERM   (France)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Deletion constructs; Functional promoter analyses; Genetic variants; Osteoprotegerin; Transcriptional control

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; NUCLEAR FACTOR I; OSTEOPROTEGERIN; TRANSCRIPTION FACTOR SP1; MESSENGER RNA; NEUROFIBROMIN;

ALLELE; ARTICLE; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA FLANKING REGION; GEL MOBILITY SHIFT ASSAY; GENE DELETION; GENE FUNCTION; GENE IDENTIFICATION; GENE INDUCTION; GENE STRUCTURE; HAPLOTYPE; HAPLOTYPE MAP; HUMAN; HUMAN CELL; MOLECULAR CLONING; OSTEOSARCOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA INTERACTION; TRANSCRIPTION REGULATION; WILD TYPE; BINDING SITE; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

BINDING SITES; CELL LINE, TUMOR; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HAPLOTYPES; HUMANS; NEUROFIBROMIN 1; OSTEOPROTEGERIN; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC;

EID: 70349566831     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.193532     Document Type: Article

References (31)

1. Herrmann SM, Whatling C, Brand E, Nicaud V, Gariepy J, Simon A, Evans A, Ruidavets JB, Arveiler D, Luc G, Tiret L, Henney A, Cambien F. Polymorphisms of the human matrix gla protein (MGP) gene, vascular calcification, and myocardial infarction. Arterioscler Thromb Vasc Biol. 2000;20:2386-2393.
2. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G. Spontaneous calcification of arteries and cartilage in mice lacking matrix Gla protein. Nature. 1997;386:78-81.
3. Speer MY, McKee MD, Guldberg RE, Liaw L, Yang HY, Tung E, Karsenty G, Giachelli CM. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med. 2002;196:1047-1055.
4. Schmidt-Petersen K, Brand E, Telgmann R, Nicaud V, Hagedorn C, Labreuche J, Dördelmann C, Elbaz A, Gautier-Bertrand M, Fischer JW, Evans A, Morrison C, Arveiler D, Stoll M, Amarenco P, Cambien F, Paul M, Brand-Herrmann SM Osteopontin gene variation and cardio/ cerebrovascular disease phenotypes. Atherosclerosis. In press.
5. Sandberg WJ, Yndestad A, Oie E, Smith C, Ueland T, Ovchinnikova O, Robertson AK, Muller F, Semb AG, Scholz H, Andreassen AK, Gullestad L, Damas JK, Froland SS, Hansson GK, Halvorsen B, Aukrust P. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol. 2006;26:857-863.
6. Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M, Schwartz SM, Giachelli CM, Rosenfeld ME. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/-mice. Arterioscler Thromb Vasc Biol. 2006;26: 2117-2124.
7. Ovchinnikova O, Gylfe A, Bailey L, Nordström A, Rudling M, Jung C, Bergström S, Waldenström A, Hansson GK, Nordström P. Osteopro-tegerin promotes fibrous cap formation in atherosclerotic lesions of apoE-deficient mice. Arterioscler Thromb Vasc Biol. In press
8. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004;109:2175-2180.
9. Semb AG, Ueland T, Aukrust P, Wareham NJ, Luben R, Gullestad L, Kastelein JJ, Khaw KT, Boekholdt SM. Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003. Arterioscler Thromb Vasc Biol. 2009;29: 975-1680
10. Zanke BW, Greenwood CM, Rangrej J, Kustra R, Tenesa A, Farrington SM, Prendergast J, Olschwang S, Chiang T, Crowdy E, Ferretti V, Laflamme P, Sundararajan S, Roumy S, Olivier JF, Robidoux F, Sladek R, Montpetit A, Campbell P, Bezieau S, O'Shea AM, Zogopoulos G, Cotterchio M, Newcomb P, McLaughlin J, Younghusband B, Green R, Green J, Porteous ME, Campbell H, Blanche H, Sahbatou M, Tubacher E, Bonaiti-Pellié C, Buecher B, Riboli E, Kury S, Chanock SJ, Potter J, Thomas G, Gallinger S, Hudson TJ, Dunlop MG. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet. 2007;39:989-1894
11. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichiello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cancel-Tassin G, Cussenot O, Valeri A, Andriole GL, Gelmann EP, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hunter DJ, Chanock SJ, Thomas G. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet. 2007;39:645-649. (Pubitemid 46676108)
12. Avramopoulos D, Willour VL, Zandi PP, Huo Y, MacKinnon DF, Potash JB, DePaulo JR Jr, McInnis MG. Linkage of bipolar affective disorder on chromosome 8q24: follow-up and parametric analysis. Mol Psychiatry. 2004;9:191-196.
13. Soufi M, Schoppet M, Sattler AM, Herzum M, Maisch B, Hofbauer LC, Schaefer JR. Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metab. 2004;89:3764-13748
14. Ohmori R, Momiyama Y, Taniguchi H, Tanaka N, Kato R, Nakamura H, Ohsuzu F, Nagano M, Egashira T. Association between osteopro-tegerin gene polymorphism and coronary artery disease in Japanese men. Atherosclerosis. 2006;187:215-217.
15. Brändström H, Stiger F, Lind L, Kahan T, Melhus H, Kindmark A. A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function. Biochem Biophys Res Commun. 2002;293:13-17.
16. Morinaga T, Nakagawa N, Yasuda H, Tsuda E, Higashio K. Cloning and characterization of the gene encoding human osteoprotegerin/ osteoclastogenesis-inhibitory factor. Eur J Biochem. 1998;254:685-691.
17. Dördelmann C, Telgmann R, Brand E, Hagedorn C, Schröer B, Hasenkamp S, Baumgart P, Kleine-Katthöfer P, Paul M, Brand-Herrmann SM. Functional and structural profiling of the human thrombopoietin gene promoter. J Biol Chem. 2008;283:24382-24391.
18. Grabe N. AliBaba2: context specific identification of transcription factor binding sites. In Silico Biol. 2001;2:S1-15.
19. Frohman MA, Dush MK, Martin GR. Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer. Proc Natl Acad Sci U S A. 1988;85:8998-9002.
20. Liu S, Spinner DS, Schmidt MM, Danielsson JA, Wang S, Schmidt J. Interaction of MyoD family proteins with enhancers of acetylcholine receptor subunit genes in vivo. J Biol Chem. 2000;275:41364-41368.
21. Schreiber E, Matthias P, Muller MM, Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res. 1989;17:6419.
22. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, Boer-winkle E, Hobbs HH, Cohen JC. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007;316:1488-1491.
23. The Wellcome Trust Case Control Consortium. Nature. 2007;447: 661-678.
24. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Tsuda E, Morinaga T, Higashio K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteopro-tegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclasto-genesis in vitro. Endocrinology. 1998;139:1329-1337.
25. Telgmann R, Dördelmann C, Brand E, Nicaud V, Hagedorn C, Pavenstädt H, Cambien F, Tiret L, Paul M, Brand-Herrmann SM. Molecular genetic analysis of a human insulin-like growth factor 1 promoter P1 variation. FASEB J. 2009;23:1303-1313.
26. Cogswell PC, Mayo MW, Baldwin AS Jr. Involvement of Egr-1/RelA synergy in distinguishing T cell activation from tumor necrosis factor-alpha-induced NF-kappa B1 transcription. J Exp Med. 1997;185: 491-497.
27. Chapman NR, Perkins ND. Inhibition of the RelA(p65) NF-kappaB subunit by Egr-1. J Biol Chem. 2000;275:4719-4725.
28. Tan L, Peng H, Osaki M, Choy BK, Auron PE, Sandell LJ, Goldring MB. Egr-1 mediates transcriptional repression of COL2A1 promoter activity by interleukin-1beta. J Biol Chem. 2003;278:17688-17700.
29. Rupp RA, Kruse U, Multhaup G, Gobel U, Beyreuther K, Sippel AE. Chicken NFI/TGGCA proteins are encoded by at least three independent genes: NFI-A, NFI-B and NFI-C with homologues in mammalian genomes. Nucleic Acids Res. 1990;18:2607-2616.
30. Kruse U, Qian F, Sippel AE. Identification of a fourth nuclear factor I gene in chicken by cDNA cloning: NFI-X. Nucleic Acids Res. 1991; 19:6641.
31. Rafty LA, Santiago FS, Khachigian LM. NF1/X represses PDGF A-chain transcription by interacting with Sp1 and antagonizing Sp1 occupancy of the promoter. EMBO J. 2002;21:334-343.